Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma
- PMID: 8425966
- DOI: 10.1016/0190-9622(93)70003-c
Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma
Abstract
Background: There is an increased risk of new basal cell carcinomas (BCCs) developing in a person who has had a BCC.
Objective: This study attempts to define the magnitude of this increased risk.
Methods: The charts of 260 white patients with a histologically proven BCC were reviewed for the occurrence of new BCCs. The cumulative 5-year incidence (modified life-table method) for new BCCs developing in these patients was compared with the 5-year incidence in the general white population of the United States.
Results: Of the 260 patients, new BCCs developed in 137 within an average of 38.3 months, a 5-year cumulative rate of one or more new BCCs of 45.2%. The yearly risk for new BCCs developing in the study population remained high during the 5-year interval. In the general white population of the United States, the maximal 5-year incidence was calculated to be 5% (p < 0.005, chi-square test).
Conclusion: Patients with a history of BCC require life-long follow-up because of the high probability of new BCCs developing.
Similar articles
-
Cumulative risks and rates of subsequent basal cell carcinomas in the Netherlands.Br J Dermatol. 2011 Oct;165(4):874-81. doi: 10.1111/j.1365-2133.2011.10488.x. Br J Dermatol. 2011. PMID: 21711333
-
Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis.Arch Dermatol. 2000 Dec;136(12):1524-30. doi: 10.1001/archderm.136.12.1524. Arch Dermatol. 2000. PMID: 11115165
-
Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation.J Am Acad Dermatol. 2007 Jan;56(1):91-5. doi: 10.1016/j.jaad.2006.07.007. J Am Acad Dermatol. 2007. PMID: 17190625 Clinical Trial.
-
Burden of basal cell carcinoma in USA.Future Oncol. 2015 Nov;11(22):2967-74. doi: 10.2217/fon.15.180. Epub 2015 Oct 15. Future Oncol. 2015. PMID: 26466906 Review.
-
The therapeutic dilemma of basal cell carcinoma in older adults: A review of the current literature.J Geriatr Oncol. 2023 Apr;14(3):101475. doi: 10.1016/j.jgo.2023.101475. Epub 2023 Mar 27. J Geriatr Oncol. 2023. PMID: 36990928 Review.
Cited by
-
Multiple nonsyndromic acquired basal cell carcinomas : Uncommon clinical presentation in a Bulgarian patient.Wien Med Wochenschr. 2017 Apr;167(5-6):134-138. doi: 10.1007/s10354-017-0545-7. Epub 2017 Feb 20. Wien Med Wochenschr. 2017. PMID: 28220371
-
The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.Ann Rheum Dis. 2012 Jun;71(6):869-74. doi: 10.1136/annrheumdis-2011-200622. Epub 2012 Jan 12. Ann Rheum Dis. 2012. PMID: 22241900 Free PMC article.
-
Proportion of Japanese Patients with Multiple Basal Cell Carcinomas: The Effectiveness of Screening.J Plast Reconstr Surg. 2024 Nov 8;4(3):169-172. doi: 10.53045/jprs.2024-0034. eCollection 2025 Jul 27. J Plast Reconstr Surg. 2024. PMID: 40755472 Free PMC article.
-
Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management.Yale J Biol Med. 2015 Jun 1;88(2):167-79. eCollection 2015 Jun. Yale J Biol Med. 2015. PMID: 26029015 Free PMC article. Review.
-
Health economic evaluation of non-melanoma skin cancer and actinic keratosis.Pharmacoeconomics. 2004;22(2):83-94. doi: 10.2165/00019053-200422020-00002. Pharmacoeconomics. 2004. PMID: 14731050 Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical